Alkermes (ALKS) Cash from Investing Activities Growth (1y) (2011 - 2026)
Alkermes (ALKS) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | 91.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.75% |
| Mar 31, 2026 | -22,919.16% |
| Dec 31, 2025 | 2,423.21% |
| Sep 30, 2025 | 93.84% |
| Jun 30, 2025 | -156.34% |
| Mar 31, 2025 | 122.78% |
| Dec 31, 2024 | 33.87% |
| Sep 30, 2024 | 8.40% |
| Jun 30, 2024 | -57.09% |
| Mar 31, 2024 | -154.84% |
| Dec 31, 2023 | -175.64% |
| Sep 30, 2023 | -1,441.41% |
| Jun 30, 2023 | 398.11% |
| Mar 31, 2023 | 220.13% |
| Dec 31, 2022 | 3,838.54% |
| Sep 30, 2022 | 128.06% |
| Jun 30, 2022 | -1,119.31% |
| Mar 31, 2022 | -60.72% |
| Dec 31, 2021 | 97.89% |
| Sep 30, 2021 | -285.40% |